文献速递艾滋病与性传播感染

利匹韦林长效制剂肌内注射的人群药代动力学

Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

模型采用一室模型、线性消除和双吸收通路,估计表观消除半衰期为200天。协变量均无临床相关影响,提示无需按亚组调整剂量。

要点

  • 利匹韦林长效制剂肌内注射后呈翻转药代动力学,表观消除半衰期约200天。
  • 年龄、体重、BMI、性别、种族、健康状况和针长对药代动力学无临床相关影响。
  • 每月方案为口服导入4周后给予900 mg起始注射,随后每4周600 mg维持注射。

核心结论

  • 群体药代动力学模型能合理描述利匹韦林长效制剂肌内注射后的血药浓度时间进程及变异性。
  • 协变量对利匹韦林药代动力学无临床相关影响,提示无需针对特定亚组调整利匹韦林长效制剂剂量。

研究设计与样本

  • 剂量范围为300至1200 mg,包括单次或多次给药方案(每4周或每8周一次)。
  • III期研究采用900 mg起始注射后每4周600 mg维持注射。
  • 使用NONMEM®软件进行非线性混合效应建模。

主要发现

  • 最终模型为一室模型、线性消除和两条平行吸收通路(快和慢)及序贯零级-一级过程,充分捕捉了肌内注射长效制剂后的翻转药代动力学。
  • 利匹韦林长效制剂的估计表观消除半衰期为200天。
  • 评估的协变量(年龄、体重、BMI、性别、种族、健康状况和针长)均无临床相关影响。

关键数值与推荐

  • 每月方案包括口服导入期(利匹韦林25 mg片剂每日一次,共4周),随后给予900 mg利匹韦林长效制剂起始注射,之后每4周600 mg维持注射。

临床怎么用

  • 基于群体药代动力学分析,利匹韦林长效制剂无需根据年龄、体重、BMI、性别、种族、健康状况或针长调整剂量。
  • 临床可采用每月方案:口服导入4周后,900 mg起始注射,随后每4周600 mg维持注射。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To characterize the population pharmacokinetics of the rilpivirine long-acting (LA) formulation after intramuscular administration. METHODS: Rich and sparse rilpivirine plasma concentration data were obtained from seven clinical studies. In total, 18 261 rilpivirine samples were collected from 986 subjects (131 healthy subjects from Phase I studies and 855 people living with HIV from Phase IIb/III studies). Doses ranged from 300 to 1200 mg, as single-dose or multiple-dose regimens (every 4 or 8 weeks). In Phase III studies, an initiation injection of 900 mg followed by continuation injections of 600 mg every 4 weeks was used. Non-linear mixed-effects modelling was performed using NONMEM® software. RESULTS: A one-compartment model with linear elimination and two parallel absorption pathways (fast and slow) with sequential zero-first-order processes adequately captured rilpivirine flip-flop pharmacokinetics after intramuscular administration of the LA formulation. The estimated apparent elimination half-life of rilpivirine LA was 200 days. None of the evaluated covariates (age, body weight, BMI, sex, race, health status and needle length) had a clinically relevant impact on rilpivirine pharmacokinetics. CONCLUSIONS: The population pharmacokinetic model suitably describes the time course and associated variability of rilpivirine plasma concentrations after rilpivirine LA intramuscular administration. The monthly regimen consists of an oral lead-in period (rilpivirine 25 mg tablets once daily for 4 weeks), followed by an initiation injection of 900 mg rilpivirine LA, then 600 mg rilpivirine LA continuation injections monthly. The absence of a clinically relevant effect of covariates on rilpivirine pharmacokinetics suggests that rilpivirine LA dose adjustments for specific subgroups are not warranted.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Neyens M, Crauwels HM, Perez-Ruixo JJ, et al. Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV. J Antimicrob Chemother. 2021. PMID: 34510179. doi:10.1093/jac/dkab338

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。